O. O. Yegit Et Al. , "Omalizumab as a premedication in venom immunotherapy: When is it indicated in systemic mastocytosis?," Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , vol.74, Lisbon, Portugal, pp.525-526, 2019
Yegit, O. O. Et Al. 2019. Omalizumab as a premedication in venom immunotherapy: When is it indicated in systemic mastocytosis?. Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , (Lisbon, Portugal), 525-526.
Yegit, O. O., Demir, S., Unal, D., Colakoglu, B., Buyukozturk, S., & Gelincik, A., (2019). Omalizumab as a premedication in venom immunotherapy: When is it indicated in systemic mastocytosis? . Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) (pp.525-526). Lisbon, Portugal
Yegit, O. Et Al. "Omalizumab as a premedication in venom immunotherapy: When is it indicated in systemic mastocytosis?," Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Lisbon, Portugal, 2019
Yegit, O. O. Et Al. "Omalizumab as a premedication in venom immunotherapy: When is it indicated in systemic mastocytosis?." Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , Lisbon, Portugal, pp.525-526, 2019
Yegit, O. O. Et Al. (2019) . "Omalizumab as a premedication in venom immunotherapy: When is it indicated in systemic mastocytosis?." Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , Lisbon, Portugal, pp.525-526.
@conferencepaper{conferencepaper, author={O. O. Yegit Et Al. }, title={Omalizumab as a premedication in venom immunotherapy: When is it indicated in systemic mastocytosis?}, congress name={Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI)}, city={Lisbon}, country={Portugal}, year={2019}, pages={525-526} }